ImmuPharma PLC (AIM:IMM, FRA:25I) has signed up Kymos Group as its bioanalytical partner for diabetes drug Kapiglucagon. That completes the outsourced team needed to file for human trials in the US. ValiRx PLC (AIM:VAL, FRA:EAJF) is set to get a second European patent for its cancer-killing peptide from subsidiary Cytolytix. It's targeting triple negative breast cancer and is in talks with a major pharma company. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) has drilled some strong copper and silver hits at its Mushima North project in Zambia. Lab results are due in the coming weeks, with a resource estimate targeted by the end of the year. Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) has kept its 2026 gold production target after output jumped 18% quarter on quarter. Revenue, profit and earnings per share were all up sharply too. Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) will talk to shareholders after a third voted against its new equity pay plan. All resolutions still passed, and the CEO says big catalysts are coming over the next year. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

ValiRx, the AIM-listed life sciences company focused on early-stage cancer therapeutics and women's health, has raised up to £1.155 million through a placing, subscription, and planned retail offer at 0.2p per share. The shares fell 17% to 0.2p, matching the issue price, which itself...